Therapure Biopharma Inc. announces agreement with large European fractionator

TORONTO, ON: October 28, 2008 – Therapure Biopharma Inc, a Canadian biopharmaceutical company that specializes in developing, manufacturing, purifying, and packaging biological protein therapeutics, today announced that it has signed a Memorandum of Understanding with a large European fractionator to pursue a long-term collaboration involving biopharmaceutical development and biomanufacturing services. This is a significant milestone for both companies and it enables Therapure Biopharma to apply its expertise in downstream protein purification to a selection of plasma-derived medicinal products. "Therapure Biopharma is thrilled to create a partnership that has the potential to bring essential protein-based medicines to world markets," said Thomas Wellner, President and CEO of Therapure Biopharma. "We are pleased that our unique cGMP biopharmaceutical manufacturing facilities, and our wealth of expertise in developing and implementing biopharmaceutical manufacturing processes, can be used to extend the extensive product capabilities of our partners and customers." Many life-saving treatments are derived from blood plasma and its constituent proteins, and the process of manufacturing these important therapeutics is complex. Therapure Biopharma and its partners combine their respective capabilities to increase the global supply of these therapeutics. About Therapure Biopharma: Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market. For more information, please visit: Media Contact: Thomas Wellner, President and CEO Therapure Biopharma Inc. +1 905-286-6204